Reindl Markus, Kuenz Bettina, Berger Thomas
Neuroimmunological and Multiple Sclerosis Clinic and Research Unit, Clinical Department of Neurology, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria.
Results Probl Cell Differ. 2010;51:99-113. doi: 10.1007/400_2008_16.
Increasing research activities on humoral immune responses involved in the immunopathogenesis of multiple sclerosis (MS) led to a revival of the importance of B cells and antibodies in MS. B cells seem now to play various immunopathogenetic roles in the initiation and propagation of inflammatory demyelinating processes at different disease stages of MS. The biological activities of antibodies in MS is, in general, still less known, although it emerges that antibodies are specifically involved in demyelination or, at least, mirror tissue destruction in the central nervous system. Finally, there is growing evidence that treatments, which specifically target B cells and/or antibodies, are effective in MS and its variants neuromyelitis optica (NMO). This chapter therefore aims to summarize the present knowledge and to outline future directions about the role of B cells and antibodies in research and therapy of MS and NMO.
对多发性硬化症(MS)免疫发病机制中体液免疫反应的研究活动不断增加,使得B细胞和抗体在MS中的重要性得以重新凸显。如今,B细胞似乎在MS不同疾病阶段的炎症性脱髓鞘过程的起始和传播中发挥着多种免疫发病机制作用。尽管有迹象表明抗体特别参与了脱髓鞘过程,或者至少反映了中枢神经系统中的组织破坏,但MS中抗体的生物学活性总体上仍不太清楚。最后,越来越多的证据表明,专门针对B细胞和/或抗体的治疗方法对MS及其变异型视神经脊髓炎(NMO)有效。因此,本章旨在总结目前关于B细胞和抗体在MS及NMO研究和治疗中的作用的知识,并概述未来的方向。